Outclassed by Eliquis, Bayer Halts Atrial Fibrillation Study of Factor XIa Inhibitor
Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS’s and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.
Outclassed by Eliquis, Bayer Halts Atrial Fibrillation Study of Factor XIa Inhibitor Read More »
